1 / 18

NeTT : Network of Translational Technologies

NeTT : Network of Translational Technologies. Mark W. Geraci, MD Associate Director, CCTSI Professor of Medicine. Specific Aims (or Objectives) CCTSI 2.0.

alec-mccullough
Télécharger la présentation

NeTT : Network of Translational Technologies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NeTT: Network of Translational Technologies Mark W. Geraci, MD Associate Director, CCTSI Professor of Medicine

  2. Specific Aims (or Objectives)CCTSI 2.0 SA 5) Strengthen our integrated Network of Translational Technologies (NeTT) and laboratories that provide state-of-the-science services for comprehensive clinical and translational research. • We will implement a Core Laboratories Tracking & Management System to centralize tracking of the broad range of translational technology resources available to CCTSI members. A major focus is to accurately track utilization to improve cost-efficiencies and prioritization of resource allocation.

  3. Governance

  4. Approach

  5. Approach - Innovation • Although rodent models serve an important purpose in moving studies of disease and therapy forward, there is much to be realized by capitalizing on availability of naturally occurring disease in outbred species with greater genetic, phenotypic, dietary, and morphologic similarities to humans.

  6. Approach - Innovation • Drawing on the strengths of a world-class clinical faculty, this center will provide opportunities to clinically evaluate • drugs, • surgical interventions, • diagnostics and devices, • in naturally occurring, well- characterized diseases of companion and domestic animal species that recapitulate human diseases.

  7. Approach – Budget Adaptation

  8. Metrics

  9. Metrics

  10. Metrics

  11. National CTSA Consortium Involvement • T1 Translational Key Function Committee • Mark Geraci, Member • Monthly calls • Best Practices for Methods Development • Novel and Innovative Technologies Demonstrations • Attempts at National Convergence • Databases of Service

  12. Response to EAC Critiques • Not Reviewed last time • Some important points raised in the peer review

  13. Response to EAC Critiques • Thanks !!

  14. Response to EAC Critiques • We purposefully placed these functions with Dr. Kohrt, in alignment • CTRC Cores are (human) clinical-based and NeTT are research-oriented

  15. Response to EAC Critiques • Due to broad inclusion, nearly all scientists are CCTSI-affiliated • OR….They become affiliated at the time of Core Use

  16. Response to EAC Critiques

  17. Questions for EAC • What about the direction of revenue for Cores through Industry / Clinical partnerships? • Is it within our mission? • How to resolve potential conflicts? • Biobanks and “Personalized / Precision Medicine” • How should this be prioritized? • How does this effort support the new Division / Center of Bioinformatics and Personalized Medicine?

More Related